Charles B. O'Keeffe - 14 Feb 2025 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Reporting relationship: Director
Issuer ticker: CPRX
Reported as of: 14 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Feb 2025, 17:00:20 UTC
Prior SEC filing: 31 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Charles B. O'Keeffe

Key filing fact

Charles B. O'Keeffe filed Form 4 for CATALYST PHARMACEUTICALS, INC. (CPRX) on 19 Feb 2025.

Key facts

This page summarizes Charles B. O'Keeffe's Form 4 filing for CATALYST PHARMACEUTICALS, INC. (CPRX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Feb 2025, 17:00.

Change

Previous filing in this sequence was filed on 31 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CPRX transaction

Common Stock, par value $0.001 per share

Options Exercise

Transaction value
Shares: +4,000
Change %: +0.55%
Price
Shares after: 732,470
Date: 14 Feb 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CPRX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -4,000
Change %: -1.9%
Price: $0.000000
Shares after: 208,274
Date: 14 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,000
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.

Footnote F2

Derivative securities vested in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025.

Footnote F3

Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The final tranche of shares was delivered on February 14, 2025.